Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder And Post-Traumatic Stress Disorder At The Society Of Toxicology 2025 Annual Meeting And ToxExpo
Alzamend Neuro將在2025年毒理學會年會上和ToxExpo上介紹AL001的藥代動力學非臨床數據更新，AL001是一種鋰水楊酸鹽/L-脯氨酸共晶，可能成爲雙相障礙類型1、阿爾茨海默病、重度抑鬱障礙和創傷後應激障礙的有益鋰節省治療。
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder
演講主題是AL001的藥代動力學，AL001是一種鋰水楊酸鹽/L-脯氨酸共晶，可能成爲雙相障礙類型1、阿爾茨海默病、重度抑鬱障礙和創傷後應激障礙的有益鋰節省治療。
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.
Alzamend Neuro, Inc.（納斯達克：ALZN）（"Alzamend"），是一家臨床階段生物製藥公司，專注於開發治療阿爾茨海默病（"阿爾茨海默病"）、雙相障礙（"BD"）、重度抑鬱障礙（"MDD"）和創傷後應激障礙（"PTSD"）的新產品，今天宣佈將在2025年3月16日至20日在佛羅里達州奧蘭多舉行的毒理學會（"SOT"）年會上和ToxExpo上進行海報展示。
譯文內容由第三人軟體翻譯。